2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1873

Use Of Mendelian Randomization Associates Increased Serum Urate Caused By Genetic Variation In Uric Acid Transporters With Improved Renal Function
Abstract Number: 866

Use Of Non Steroidal Anti-Inflammatory Drugs Prevent Bone Loss In Patients With Early Inflammatory Back Pain: Results From The DESIR Cohort
Abstract Number: 1054

Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Abstract Number: 432

Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Abstract Number: 1040

Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
Abstract Number: 2007

Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes
Abstract Number: 2867

Using Patient Reported Outcomes Measurement Information System Instruments To Identify Disease Flares In People With Rheumatoid Arthritis
Abstract Number: 1798

Ustekinumab For The Treatment Of Patients With Active Ankylosing Spondylitis: Results Of a 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS)
Abstract Number: 322

Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From 2 Phase 3, Randomized, Placebo-Controlled Trials
Abstract Number: 1695

Ustekinumab Is Effective In Inhibiting Radiographic Progression In Patients With Active Psoriatic Arthritis: Integrated Data Analysis Of Two Phase 3, Randomized, Placebo-Controlled Studies
Abstract Number: 2087

Utility and Reliability Of Digital Nailfold Capillaroscopy In Children With Juvenile Dermatomyositis: Three Methods
Abstract Number: 1111

Utility Of An Ultrasound Enthesitis Score As a Complementary Diagnostic Tool To Detect Psoriatic Arthritis In Patients With Psoriasis
Abstract Number: 2575

Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
Abstract Number: 991

Utilization Of An Informational Needs Assessment To Develop An Education Program For Patients With Ankylosing Spondylitis (AS) and Related Axial Spondyloarthritis (SpA)
Abstract Number: 990

Utilizing Facebook Chats To Convey Health Information To Lupus Patients At The Systemic Lupus Erythematosus – Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].